Dx Deals: New Premerger Regulations Could Slow Down Pace of Transactions
The new rules, which were approved by the FTC in October and will go into effect in mid-January, aim to put a damper on consolidation
The new rules, which were approved by the FTC in October and will go into effect in mid-January, aim to put a damper on consolidation
The roughly $1 billion deal will boost the company’s annual revenue by about 7 percent, and will give Quest a stronger presence in Canada
Though the two national players have closed dozens of such deals over the past decade, much runway for new transactions apparently remains
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Most of Invitae's employees will be hired by Labcorp, which expects the deal to add about $275 million in annual revenue
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
Partnership between Mindera and PBM aims to optimize treatment matches for the disorder, as some drugs cost nearly six figures annually
Both companies have made recent moves to diversify further.
More aggressive use of artificial intelligence may mitigate issues that lead to the uneven impact of the disease on this group.
An overview of the key 2023 mergers and acquisitions in the diagnostics industry and the trends they reveal.
While Roche has an early lead, Quest recently made key moves to improve its position in the AD patient-initiated blood testing market.